| Similar Articles |
|---|
 |
Bio-IT World
June 2005
Maureen McDonough |
Celera Releases Genome Data In a decision that essentially marks the end of the genome wars, Celera Genomics will release its formerly proprietary human, mouse, and rat genome sequences to the public domain.   |
Bio-IT World
March 17, 2004 |
Genome War and Peace The belated result is a fluid and frequently compelling book, with some fascinating insights into the commercial and political wrangling that accompanied the creation of Celera and ultimately undermined Venter's goal of becoming the Bloomberg of genomics. |
Bio-IT World
November 12, 2002
Davies et al. |
John Craig Venter Unvarnished The former Celera CEO talks about that company's politics, the future of sequencing technology, and his own genome. |
Bio-IT World
June 2005
John Russell |
A Totally Spooky Evening Paul Mullin's wonderful play, The Sequence, spills out the sometimes sordid details of the rivalry between the two men who were at the heads of the institutions racing to sequence the human genome. |
Bio-IT World
March 8, 2005
Melissa Trudinger |
Craig Venter: In Darwin's Wake Since leaving Celera Genomics in 2003, J. Craig Venter has turned his attention from mining the human genome to exploring the life forms of the oceans. Here, he talks about his voyage. |
BusinessWeek
December 13, 2004
John Carey |
Craig Venter: DNA's Mapmaker Who could ever have imagined that a surfer working as a night clerk at Sears, Roebuck & Co. would eventually become the driving force behind the race to read the genetic code of humanity? |
Fast Company
September 2000
John Ellis |
The Secret of Life The mapping of the human genome, says Craig Venter, will change science, research, medicine, politics, health insurance, and the way biology looks at the last 3 billion years of evolution. And that's just the beginning. |
Bio-IT World
February 18, 2004 |
Smokin' Supercomputing Paracel's Jason Molle on solving the IT challenges of biological analysis |
The Motley Fool
December 30, 2008
Brian Orelli |
A Post-Holiday Breakup ... of Sorts Abbott and Celera revise their partnership. |
The Motley Fool
April 14, 2011
Brian Orelli |
Human Genome Sciences Will Be Profitable, Eventually With its first drug on the market -- nearly 20 years after the company was founded -- Human Genome Sciences should start to show meaningful revenue this year. |
Bio-IT World
July 15, 2003
Salvatore Salamone |
Buying Power Celera's decision to replace its Compaq supercomputer with IBM and EMC is surprising. It also provides a fascinating how to procurement model for the bio-IT industry. |
Salon.com
June 26, 2000
Ralph Brave |
The great gene race A tiny private company and the giant public genome project jointly crossed the finish line. But the upstart really won. |
Salon.com
June 27, 2000
Tabitha M. Powledge |
Book of life? Hosanna! The Human Genome Project has been completed. We will now cure diseases, weed out defective genes and create a new supergeneration in the near future. Not. |
Bio-IT World
May 2006
Kevin Davies |
Ashburner Receives Bioinformatics Benjamin Franklin Award A noted Drosophila researcher who helped lead the project to sequence the fruit fly genome in the late 1990s, Michael Ashburner was lauded for his steadfast championing of open-source resources for the genetics and informatics communities. |
Bio-IT World
October 9, 2002
Kevin Davies |
Cracking the 'Druggable Genome' How many potential drug targets are encoded in the human genome? It is a crucial question for every biopharma business. |
Bio-IT World
February 10, 2003
Kevin Davies |
With a Click of the Mouse What do Eminem and Mus musculus have in common? About 30,000 genes, for a start. The author mulls over the second mammalian genome. |
Bio-IT World
August 15, 2005
Kevin Davies |
Pimp My Genome As costs plummet, the ability to rapidly synthesize and customize longer, more intricate fragments of genomic DNA opens up a plethora of applications in basic and applied biology. A commercial synthetic biology industry is beginning to take shape. |
Bio-IT World
August 18, 2004 |
Little News Is Good News Hopes that a burst of high-flying IPOs would fan investor interest in biotechnology were dashed in Q2, as several companies had to accept much lower prices than anticipated. |
Pharmaceutical Executive
May 1, 2006
Sunshine K. Mugrabi |
Back Page: Risk Assessment New thinking and diagnostic tests may change how statins are marketed and prescribed. |
Bio-IT World
June 15, 2003
Elizabeth Gardner |
Mouse Hunt The deluge of data and accompanying proliferation of databases is spiraling out of control. New federations and solutions may offer partial relief. |
Bio-IT World
February 2006
Kevin Davies |
Solexa Readies 1G Genetic Analyzer Solexa, one of the firms vying to crack the $1,000 genome threshold, has officially launched its first commercial genome sequencing instrument. |
Bio-IT World
October 2006
Michael A. Greeley |
What Use Is the $1,000 Genome? Industry is focused on the $1,000 genome -- but investors want to see revenue and profits. The goal of simply reaching the $1,000 genome threshold inherently lacks a business model. What are the applications or products or services that will be unleashed by reaching that milestone? |
Wired
August 2000
Jennifer Hillner |
Area 22 The inside story of the first fully sequenced chromosome. |
Bio-IT World
July 14, 2004
Malorye A. Branca |
The Maven of Microarrays Affymetrix Research Institute's CEO, Stephen Fodor, discusses building a tech business without a blueprint |
The Motley Fool
October 5, 2010
Brian Orelli |
You Should Have Seen this FDA Rejection Coming This hepatitis C treatment was marked for failure. |
Bio-IT World
November 12, 2002
Kevin Davies |
DNA for Dummies? The journal Nature Genetics has just published a user's guide to the human genome -- and none too soon. |
Bio-IT World
December 10, 2002 |
Craig Venter Unvarnished (part II) The former Celera CEO covers privacy, ESTs, and his new research institutes. |
The Motley Fool
September 18, 2007
Brian Orelli |
Another Partnership for Personalized Medicine Celera gets a contract to design a companion diagnostic test for Merck. Investors, take note. |
Salon.com
February 13, 2001
Arthur Allen |
Size doesn't matter As scientists unveil the human genome findings, it turns out we have a lot fewer genes than we'd thought, and not many more than a fruit fly... |
The Motley Fool
March 17, 2011
Brian Orelli |
Eat or Be Eaten? Perhaps Both. Oft-rumored takeout target Human Genome Sciences goes shopping. |
AskMen.com
Ross Bonander |
5 Things You Didn't Know: DNA With human cloning and other controversial bombshells waiting just around the corner, expect DNA to remain in the public eye for decades to come. |
Wired
December 2002
Douglas McGray |
Supermicrobe Man First Craig Venter cracked the human genome. Now he wants to sequence the ocean and save the world. |
Bio-IT World
March 2006
Kevin Davies |
Church Inquiry Gets Personal Harvard Medical School geneticist George Church with his plan for the Personal Genome Project is a likely contender for the X Prize that will be awarded to the group or individual that most helps cross the $1,00 genome threshold. |
Salon.com
February 26, 2002
Annalee Newitz |
Genome liberation The information that details who we are is too important to be privately owned... |
The Motley Fool
March 26, 2004
Charly Travers |
Human Genome Getting on Track What a novel concept for a drug company to focus on commercializing drugs. |
Bio-IT World
April 15, 2003
Malorye Branca |
Beyond the Blueprint How will the wealth of data emanating from the human genome and allied technologies impact research on health and disease? |
Bio-IT World
September 16, 2004
Kevin Davies |
Computing the Genome Boston University's Charles DeLisi explains his involvement with the human genome project and why he has recently turned his attention to systems biology and an AIDS vaccine. |
The Motley Fool
October 27, 2010
Ralph Casale |
Companion Diagnostics in Cancer Drug Development Diagnostic companies partnering with drug developers can make for an attractive investment segment. |
Information Today
August 4, 2011 |
Elsevier Introduces Genome Viewer The Genome Viewer is a SciVerse application that displays detailed gene or genomic sequence information on the genes mentioned in an article. |
Bio-IT World
January 21, 2005
Kevin Davies |
Simulated Shades of Jurassic Park? Bioinformatics researchers have re-created part of the genome sequence of an ancestral mammal that lived 70 million to 80 million years ago. |
Bio-IT World
August 15, 2005
John Russell |
Reasons for Optimism Submissions to the 2005 Bio-IT World Best Practices Awards Program included a description of a systems of hieroglyphic representations of proteins, a platform for integrative genomics, and a number of entries that saved man hours by utilizing client management tools. |
Wired
June 23, 2008 |
Expired-Tired-Wired Trends in desserts, Internet privacy protection, and genomes. |
Bio-IT World
November 12, 2002
James Golden |
The Business of Bioinformatics The industry has reached an interesting crossroads. As an academic branch of learning, bioinformatics remains mostly what it always was, a cross-disciplinary endeavor between computer science and molecular biology. But bioinformatics as a money-making proposition has different criteria for success. |
Bio-IT World
September 2005
Kevin Davies |
Fantastic 454: DNA Sequencing Pyrotechnics In an exciting advance for DNA sequencing technology, a research team at 454 Life Sciences Corp. has essentially sequenced and assembled a bacterial genome sequence based on a mere 4-hour run on the company's proprietary instrument. |
Fast Company
November 2009
David H. Freedman |
The Gene Bubble: Why We Still Aren't Disease-Free When the human genome was first sequenced nearly a decade ago, the world lit up with talk about how new gene-specific drugs would help us cheat death. Well, the verdict is in: Keep eating those greens. |
The Motley Fool
July 22, 2010
Rich Smith |
This Just In: Upgrades and Downgrades Baird turns bullish on Human Genome Sciences. |
Bio-IT World
August 13, 2003
Michael Greeley |
Two Cents on the '$1,000 Genome' Are venture capitalists still looking for 'the killer app'? Funding the next big idea won't be so easy. Affordable, individualized genome sequencing holds great promise, but making the claims sound too grandiose can be dangerous. |
The Motley Fool
December 14, 2004
Charly Travers |
Genetics of a Rule Breaker Investing is a lifelong learning process. We never know everything, but it is important we strive to learn from the lumps we take along the way. Here are some hard-earned tips from a biotech investor. |
Bio-IT World
August 18, 2004
Kevin Davies |
Bio IT World President's Award: Francis Collins The director of the National Human Genome Research Institute (NHGRI) spoke of collaboration and computation during his acceptance speech. |
Bio-IT World
Dec 2006/Jan 2007
Kevin Davies |
The One Percent Difference New research reveals a shocking new layer of human genome variation with profound implications for the future of genomic analysis and personalized medicine. |
